19 September 2018

In Clinical Gastroenterology and Hepatology Peter Siersema and Yonne Peters, theme Tumors of the Digestive Tract, showed that patients with stable persistence of non-dysplastic Barrett’s esophagus have a low risk of malignant progression and may not benefit from routine endoscopic surveillance.


Background and aims:
The risk of esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett's esophagus (NDBE) is low, so there is debate over the role of ongoing surveillance for patients with NDBE. It is important to identify patients at low risk for progression. We assessed cancer risk based on the subsequent number of endoscopies showing persistence of NDBE in a nationwide study in the Netherlands.
In a population-based study, patients with a first diagnosis of NDBE were selected from the Dutch nationwide registry of histopathology. We calculated incidence rates and incidence rate ratios (IRR) for high-grade dysplasia (HGD) and EAC to determine whether the number of endoscopies negative for dysplasia and the persistence of NDBE over time associate with progression to malignancy.
We identified 12,728 patients with NDBE during 2003 and 2013. HGD or EAC developed in 436 patients (3.4%) during 64,537 person-years of follow up (median, 4.9 years). The rate of progression to HGD or EAC was 0.68 (95% CI, 0.61-0.74) per 100 person-years. In patients with 2 consecutive endoscopies showing NDBE, the rate of progression to HGD or EAC decreased to 0.55 (95% CI, 0.46-0.64) per 100 person-years (IRR 0.72; 95% CI, 0.60-0.87). Overall, the incidence of HGD or EAC decreased by 14% for each year of progression-free follow-up (IRR, 0.86; 95% CI, 0.81-0.92).
In a population-based study in the Netherlands, we found patients with stable NDBE to have a low risk of progression to HGD or EAC. These findings indicate that surveillance intervals might be lengthened or even discontinued in subgroups patients with persistent NDBE
Incidence of Progression of Persistent Non-Dysplastic Barrett's Esophagus to Malignancy.
Peters Y, Honing J, Kievit W, Kestens C, Pestman W, Nagtegaal ID, van der Post RS, Siersema PD.

Related news items

NWO grant to develop new biomaterials for Sander Leeuwenburgh and Roland Brock

20 August 2019

Sander Leeuwenburgh (Dept. of Dentistry) and Roland Brock (Biochemistry) were recently awarded with a grant of 581 k€ by the Netherlands Organisation for Scientific Research (NWO, Domain Applied & Engineering Sciences AES) to develop new biomaterials for improved regeneration of bone defects.

read more

European Commission Initiative on Breast Cancer (ECIBC) Guidelines

13 August 2019

In Annals of internal medicine Mireille Broeders and colleagues from the ECIBC Guidelines Development Group described the methods used to develop person-centered evidence-based recommendations for screening and diagnosis of breast cancer.

read more

Circulation publication for exercise physiologists

13 August 2019

Thijs Eijsvogels and Vincent Aengevaeren showed that exercise-incuded elevations of troponin concentrations are predictive of major adverse cardiovascular events and mortality.

read more

DELA, Radboudumc and Games for Health start a new project to fight loneliness among elderly using games

12 August 2019

More than half of people aged 75 and over feel their selves lonely every now and then. A special collaboration between DELA, Radboudumc, and Games for Health will investigate whether joined gaming between elderly and young people can alleviate this social problem.

read more

Floris Schreuder received Dekker grant

6 August 2019

Floris Schreuder received one of the ten Dekker grants from the Dutch Heart Foundation (Hartstichting).

read more

A warm welcome for a new RIMLS colleague Nico Sommerdijk

5 August 2019

As of 1 August we welcome Nico Sommerdijk as our new colleague at the RIMLS. Nico will join the department of Biochemistry, with his research group “Biochemistry of Mineralized Tissues”.

read more